Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mylan Inc. (MYL - Analyst Report) recently inked a distribution agreement with the privately held Zyomyx, Inc. Following the deal, Mylan gained rights to distribute Zyomyx's point-of-care (POC) CD4 T-cell count test in developing markets. The CD4 test is applicable for patients suffering from HIV.

Pursuant to the deal, Mylan has made a strategic equity investment in the private entity. We note that the portable, easy-to-use, low-cost test is undergoing the final stages of development and is expected to be launched shortly, assuming approval. Mylan intends to distribute the product in developing markets along with its wide range of high quality, low-cost generic antiretroviral drugs to facilitate HIV treatment in those territories.
    
Furthermore, Mylan has inked a Global Access Commitment with one of the investors in Zyomix, Bill & Melinda Gates Foundation, to facilitate easy access of the POC CD4 technology to HIV patients in markets, where the disease is highly prevalent.

We note that Mylan was also in the news recently when it launched a wide range of women's care products in the highly sought after emerging market- India.

Moreover, the already established generic portfolio at Mylan was further strengthened when it launched its generic version of Pfizer Inc.’s (PFE - Analyst Report) erectile dysfunction drug Viagra (sildenafil citrate) in eleven European nations last month. Mylan’s generic unit has seen quite a few launches over the past few months. Another generic player, Dr. Reddy's Laboratories Ltd. (RDY - Snapshot Report), too has been making multiple generic launches over the past few months.

Mylan carries a Zacks Rank #3 (Hold). Simcere Pharmaceutical Group appears to be more attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%